Group 1 - CareDx (CDNA) is currently outperforming its Medical sector peers with a year-to-date return of approximately 113.7%, compared to the sector average of 2.1% [4] - The Zacks Rank for CareDx is 2 (Buy), indicating a positive outlook based on earnings estimates and revisions, with a 16.7% increase in the consensus estimate for full-year earnings over the past 90 days [3] - CareDx is part of the Medical Services industry, which has an average year-to-date loss of 5.4%, further highlighting CareDx's strong performance relative to its industry [5] Group 2 - Clover Health Investments, Corp. (CLOV) has also shown strong performance with a year-to-date return of 260.3%, and it holds a Zacks Rank of 2 (Buy) with a 7.7% increase in the consensus EPS estimate over the past three months [4][5] - The Medical sector consists of 1025 individual stocks and currently holds a Zacks Sector Rank of 3, indicating a moderate strength among its groups [2] - The Medical Services industry, which includes CareDx, ranks 138 in the Zacks Industry Rank, while the Medical Info Systems industry, which includes Clover Health, ranks 34 [5][6]

Core Viewpoint - CareDx (CDNA) shows potential for significant upside, with a mean price target of $34.67 indicating a 49.9% increase from the current price of $23.13 [1] Price Targets - The average price target consists of six estimates ranging from a low of $28 to a high of $40, with a standard deviation of $4.97, suggesting a consensus among analysts [2] - The lowest estimate indicates a 21.1% increase, while the highest suggests a 72.9% upside [2] Analyst Sentiment - Analysts exhibit strong agreement on CDNA's ability to report better earnings than previously predicted, which supports the expectation of stock upside [4] - Over the last 30 days, the Zacks Consensus Estimate for the current year has increased by 15.7%, with three estimates moving higher and no negative revisions [10] Zacks Rank - CDNA holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for near-term upside [11] Earnings Estimate Revisions - There is a strong correlation between trends in earnings estimate revisions and near-term stock price movements, suggesting that the positive revisions could lead to stock price increases [9]

CareDx (CDNA) has been on a downward spiral lately with significant selling pressure. After declining 12% over the past four weeks, the stock looks well positioned for a trend reversal as it is now in oversold territory and there is strong agreement among Wall Street analysts that the company will report better earnings than they predicted earlier.Guide to Identifying Oversold StocksWe use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting whether a stock is over ...

For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. CareDx (CDNA) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.CareDx is a member of the Medical sector. This group includes 1024 individual stocks and c ...

CareDx, Inc (NASDAQ:CDNA) Q3 2024 Earnings Conference Call November 4, 2024 4:30 PM ET Company Participants Greg Chodaczek - Managing Director John Hanna - President and Chief Executive Officer Abhishek Jain - Chief Financial Officer Conference Call Participants Bill Bonello - Craig-Hallum Mark Massaro - BTIG Brandon Couillard - Wells Fargo Yi Chen - H.C. Wainwright Mason Carrico - Stephens Inc Thomas DeBourcy - Nephron Research Operator Good day, everyone, and welcome to today's CareDx, Inc. Third Quarter ...

| --- | --- | --- | --- | --- | |-------|-------|-------|-------|-------| | | | | | | | | | | | | | | | | | | | | | | | | Safe Harbor Statement 2 These slides and the accompanying oral presentation contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact contained in this presentation, including statements regarding the future fina ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 __________________________________________________ FORM 10-Q __________________________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-365 ...

GROWTH & CareDx 2024 INVESTOR DA OCTOBER 15, 2024 E CareDx UNLOCKING GROWTH SAFE HARBOR STATEMENT These slides, and the accompanying oral presentation, contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, ar 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact contained in this presentation, including statements regardi future financial position of CareDx", Inc. (together with its subsidiari ...

Shares of CareDx Inc (CDNA, Financial) surged 6.16% in mid-day trading on Oct 2. The stock reached an intraday high of $32.97, before settling at $32.83, up from its previous close of $30.93. This places CDNA 5.77% below its 52-week high of $34.84 and 583.96% above its 52-week low of $4.80. Trading volume was 663,513 shares, 72.2% of the average daily volume of 918,408. Wall Street Analysts Forecast Based on the one-year price targets offered by 7 analysts, the average target price for CareDx Inc (CDNA, Fin ...

Since my last analysis, CareDx, Inc. (NASDAQ: CDNA ) has resolved its corporate instability and insurance coverage. It also seems to have progressed towards preventing further legal disputes with Natera ( NTRA ). This My name is Myriam Hernandez Alvarez. I received the Electronics and Telecommunication Engineering degree from the Escuela Politecnica Nacional, Quito, Ecuador, the M.Sc. degree in computer science from Ohio University, Athens, OH, USA, a graduate degree in Business Management from Universidad ...